

Toxic Anterior Segment Syndrome: A Comprehensive Review of Literature

Mohammad R. Naqeeb, MD*

ABSTRACT

Toxic anterior segment syndrome (TASS) is a sterile, acute, uncommon inflammatory response that occurs after surgery. This literature review aims to investigate TASS epidemiology, diagnosis, and management and provide updated evidence from previous TASS cases. Determining the specific TASS reason is usually challenging. TASS is associated with several complications, such as apoptosis, necrosis, and toxic cell damage. Some studies suggest that it may occur after cataract surgery among about 1 per 1,000 people who undergo surgery. Diagnosis of TASS is challenging because its signs and symptoms are like infectious endophthalmitis. The diagnosis of TASS involves laboratory tests and clinical evaluation as follows: slit lamp examination, tonometry, and examination of corrected distance visual acuity are used to distinguish the clinical characteristics of TASS. Although the treatment for TASS varies based on the severity of cases, topical corticosteroids remain the cornerstone of therapy.

Keywords: *Diagnosis; Management; Toxic anterior segment syndrome; Treatment*

INTRODUCTION

Toxic anterior segment syndrome (TASS) is a sterile, acute, uncommon inflammatory response that occurs after surgery¹. Monson and colleagues² introduced the TASS phrase first in 1992. TASS is also known as localized endophthalmitis, toxic endothelial cell destruction syndrome, sterile postoperative endophthalmitis, and toxic lens syndrome³⁻⁷. Although TASS predominantly arises after cataract operations, it is also reported after posterior segment and keratoplasty surgeries⁸⁻¹¹. TASS typically develops within 12 to 48 hours after surgery⁵. Still, late-onset cases are documented in the literature¹²⁻¹⁴. Moreover, it can present in clustered and sporadic outbreaks¹⁵.

Determining the specific TASS reason is usually challenging¹⁵, as it can develop due to multiple agents that can enter the anterior segment instantly following or during surgery and cause toxic tissue damage¹⁻³. These agents include ocular medications' additives or preservatives, detergents, denatured ophthalmic viscoelastic devices, intraocular irrigation solutions whose osmotic pressure, pH, or chemical composition are incompatible with preserving ocular tissue, and bacterial endotoxins¹⁶⁻²⁶.

TASS is associated with several complications, such as apoptosis, necrosis, and toxic cell damage⁵, in addition to other long-term complications, including iris transillumination defects, mydriasis, iris damage, corneal endothelial damage, cystoid macular edema, chronic inflammation, and glaucoma³. With the advancement of surgical techniques, technology, and new medications and substances for intraocular procedures, the frequency of these complications has increased, and new approaches have been suggested to reduce them^{5,27-30}.

TASS is preventable; therefore, it is a significant interest for surgeons³¹. TASS can be prevented by regularly researching and providing updated information about TASS to ophthalmic surgeons⁹. These may also contribute to preventing many TASS-related serious complications. Hence, this literature review aims to investigate TASS epidemiology, diagnosis, and management and provide updated evidence from previous TASS cases.

EPIDEMIOLOGY

Because TASS occurs in rare sporadic and clustered outbreaks, it is challenging to estimate its incidence. Some studies suggest that it may occur after cataract surgery among about 1 per 1,000 people who undergo surgery^{15,32}. In India, a previous study analyzed more than 20,000 cataract surgeries at Aravind Eye Hospital and found that the incidence of TASS among these cases was 0.22%³². In another prior study, 909 cases of TASS occurred in eye surgery centers in Romania, Spain, Mexico, Italy, Brazil, Argentina, and the United States after 50,114 cataract surgeries were performed at these centers from 2007 to 2009³³. In addition to equipment and solutions required during surgery, patient risk factors such as hyperlipidemia, systemic hypertension, and uncontrolled type 2 diabetes may increase the risk of TASS³⁴.

DIAGNOSIS

Diagnosis of TASS is challenging because its signs and symptoms are like infectious endophthalmitis^{35,36}. Regardless of these similarities, their treatment is different³⁷, and both are associated with poor visual outcomes³⁸. Therefore, differentiation between them is essential³⁷; the features in Table 1 can aid in this differentiation.

The diagnosis of TASS involves laboratory tests and clinical evaluation as follows: slit lamp examination, tonometry, and examination of corrected distance visual acuity (CDVA) are used to distinguish the clinical characteristics of TASS; B-scan is utilized in cases with severe anterior chamber reaction if viewing the posterior pole is challenging; and fungal culture and bacterial culture are performed to rule out any infections^{38,42,45}.

MANAGEMENT

Although the treatment for TASS varies based on the severity of cases, topical corticosteroids remain the cornerstone of therapy. Topical dexamethasone or prednisolone are used for mild cases, subconjunctival corticosteroids may be mandated for moderate cases, and oral corticosteroids may be required for severe cases⁴⁶. If patients

* College of Medicine, Umm Al-Qura University
Makkah, SAU.
Email: mrnaqeeb@uqu.edu.sa

Table 1. Clinical features for infectious endophthalmitis vs TASS^{3,15,31,38-44}.

Feature	Infectious endophthalmitis	TASS
Pain	Moderate to severe	Non or mild
Onset	3–7 days after surgery	12–48 hours after surgery
Corneal edema	Focal or no corneal edema	Limbus-to limbus corneal edema
Intraocular pressure (IOP)	Variable	Normal to elevated
Vitreous involvement	Present	Rare
Visual acuity decrease	Moderate to severe	Mild
Culture	Gram stain Culture positive	Gram stain Culture negative
Anterior chamber	Severe inflammation with hypopyon	Mild to severe inflammation with fibrin, hypopyon, flare, and/or cells
Inflammation	Involved the entire ocular cavity	Limited to the anterior chamber
Steroids treatment response	Cloud worsens, antibiotics required	Rapid response

TASS, toxic anterior segment syndrome.

Table 2. Summary of TASS cases from 16 prior studies.

Authors, year	Country	Aim	Sample size [M/F, years of age or mean age, if available]	Surgery type	Symptoms (All or some patients)	Treatment	Outcome(s)
Choi et al., 2008 ⁴⁹	Korea	Study the causalities of TASS post-phacoemulsification.	15 patients [2/13, mean age: 64.7±10.9]	Phacoemulsification	Moderate corneal edema.	Steroids NaCl solution	Conventional treatments have not shown a benefit. Using steam sterilization instead of ethylene oxide sterilization hindered the occurrence of TASS.
Ozcelik et al., 2010 ²⁴	Turkey	Assess the treatment response and the outcomes of anterior segment examination for post-uncomplicated cataract operation TASS patients.	14 patients [mean age: 64.07±5.40]	Cataract surgery	Corneal edema, visual impairment, fibrin, and hypopyon.	Steroids Antibiotic drops	It has been treated successfully.
Jun et al., 2010 ⁶⁰	Korea	Document a TASS case that was assumed to result from antiseptic solution usage.	1 patient [F, age: 78]	Cataract surgery	Anterior chamber inflammation and diffuse corneal edema.	Topical antibiotic Steroid eyedrops	Corneal edema continued, but the anterior chamber inflammation declined extensively.
Huang et al., 2010 ⁶¹	China	Document the clinical outcomes of a child TASS case following an uneventful congenital cataract operation.	1 patient [M, age: 8]	Congenital cataract surgery	Mild mydriasis, fibrin, and diffuse corneal edema.	Topical and oral steroids	Endothelial cell count declined. Visual acuity improved. Corneal edema gradually enhanced.
van Philips, 2011 ⁶²	Netherlands	Report TASS cases that emerged sequentially or post-implant foldable iris-fixated pIOL.	2 patients C1: [F, age: 45] C2: [F, age: 33]	Foldable iris-fixated pIOL implantation	Intense anterior chamber inflammation, conjunctival and ciliary injection, fibrin, hypopyon, and slight decrease in CDVA.	Intensive topical steroid	Resolved without complications.

Moyle et al., 2013 ⁴⁷	USA	Investigate causes and clinical observations of two TASS consecutive sets following uncomplicated phacoemulsification cataract operation.	11 patients [M, mean age: 68.73±6.84]	Corneal phacoemulsification	Hypopyon, fibrin, inflammatory plaques, mild to severe vision impairment, anterior chamber white blood cells, and severe stromal edema.	Steroid. Antibiotic. Diclofenac.	Corneal edema and inflammation resolved. Vision 20/20.
Koban et al., 2014 ⁵⁰	Turkey	Document a post-cataract operation TASS case that developed due to an accidental high gentamicin dose injection in the corneal stroma and anterior chamber.	1 patient [F, age: 72]	Corneal phacoemulsification	Hemorrhagic fibrinous reaction, severe corneal edema, hyphema, generalized Descemet's folds, and mild conjunctival chemosis.	Topical and oral steroids Cyclopentolate hydrochloride NaCl solution Antibiotics Ophthalmic ointment	Corneal edema persists. Descemet's folds improved. Bullous keratopathy developed. She needed penetrating keratoplasty.
Suzuki et al., 2015 ¹²	Japan	Present the clinical outcomes of TASS following implantation of aluminum-contaminated IOLs.	251 patients [89/162, mean age: 72.85]	IOL implantation	Hypopyon, fibrin, conjunctival injection, and anterior chamber cells.	57% treated with antibiotics and steroids 43% underwent surgery	BCVA improved significantly after treatment.
Sevimli et al., 2016 ¹⁰	Turkey	Report a post-uncomplicated DALK TASS case.	1 patient [F, age: 31]	DALK	Corneal edema and severe vision loss.	Oral steroids and high-dose topical steroids	Corneal edema: decreased. Visual acuity: increased.
Lee et al., 2017 ⁶³	Australia	Differentiate between the diagnosis of TASS and endophthalmitis.	1 patient [F, age: 74]	Cataract surgery	Small hypopyon, mild corneal edema, and inflammation.	Steroid Antibiotic	TASS: Overall, the prognosis was good. Steroids improve symptoms, while antibiotics worsen the condition.
Ahmad et al., 2021 ⁶⁴	Syria	Document a post-LASIK surgery TASS case.	1 patient [M, age: 42]	LASIK		Steroids	Vision recovered. Pain relieved. Inflammatory response resolved.
Arici et al., 2022 ⁶⁵	Turkey	Report a post-uneventful pterygium operation severe corneal edema case and investigate the potential causes.	1 patient [F, age: 29]	Pterygium excision surgery with conjunctival autografting	Conjunctival hyperemia, Descemet folds, and diffuse corneal edema.	Topical steroid	Within two weeks of treatment, a complete response was achieved.
Gil-Martínez et al., 2022 ⁶⁶	Venezuela	Document two post-sequential uneventful trabeculectomy operations TASS cases.	2 patients C1; [M, age: 45] C2: [F, age 63]	Trabeculectomy	Hypopyon, fibrin, moderate corneal edema, and conjunctival hyperemia.	Steroids Antibiotics	Favorable outcomes were reported.

Kaplan et al., 2022 ³⁷	Turkey	Represent the clinical treatment and characteristics considered when determining reasons for an unexpected inflammatory reaction after a post-cataract operation.	13 patients [7/6, mean age: 68.84±11.34]	Cataract surgery	Severe hypopyon, vitritis, corneal edema, pain, and blurred vision.	Topical steroid IV steroid	After 2 days of treatment, hypopyon and edema decreased. After 3 days of treatment, the hypopyon and edema completely resolved.
Ruiz-Lozano et al., 2023 ⁵²	Mexico	Report a bilateral TASS case with vitreous following bilateral phacorefractive operation.	1 patient [F, age: 59]	Phacorefractive surgery with multifocal IOL implantation	Erythema, eyelid edema, conjunctival chemosis, anterior chamber inflammation, and ciliary injection.	High-dose oral steroids and topical steroids	Significant clinical improvement has been reported.
Ginger-Eke et al., 2023 ⁵¹	Nigeria	Emphasize TASS preventive measures and potential causes and notify surgeons of the potential of TASS after anterior segment operations, such as trabeculectomy.	1 patient [M, age: 58]	Trabeculectomy	Deteriorating visual acuity, profound Descemet's folds, and severe corneal edema.	Topical steroid Systemic oral acetazolamide and steroid Timolol NaCl solution	Bullous keratopathy developed. Cornea edema continued. He was referred to another center for penetrating keratoplasty but rejected any additional intervention.

TASS, toxic anterior segment syndrome; NaCl, sodium chloride; M, male; F, female; C, case; pIOL, phakic intraocular lens; CDVA, Corrected distance visual acuity; IOLs, intraocular lenses; BCVA, best-corrected visual acuity; DALK, deep anterior lamellar keratoplasty; LASIK, laser in situ keratomileusis; IV, intravenous.

have pain, topical non-steroidal anti-inflammatory drugs (NSAIDs) can be administered⁴⁷. Topical atropine⁴⁸ or sodium chloride (NaCl)⁴⁹⁻⁵² may be utilized in some cases. Broad-spectrum antibiotic therapy is recommended because research reported that up to 30% of bacterial endophthalmitis cases can have a negative microbial culture⁵³. In subjects with elevated IOP, topical beta-blockers⁵⁴ or acetazolamide⁵⁵ are administered.

In addition, some patients may need surgical interventions. For instance, filtering procedures and penetrating keratoplasty may be required if IOP remains high among patients after medication therapy⁵⁶. Moreover, penetrating or endothelial keratoplasty can be performed for patients with corneal decomposition^{12,57}. Anterior chamber washout, intraocular lens (IOL) removal, and vitrectomy are other reported required surgical interventions for TASS patients⁵⁸. Finally, increasing awareness about TASS preventive strategies, such as minimizing enzymatic detergents and sterilizing ophthalmic instruments^{15,59}, is the most crucial measure for prevention⁹.

REVIEW OF CASES

We reviewed 16 previous studies^{10,12,24,37,47,49-52,60-66} from 2008 to 2023, including 317 reported TASS cases from Korea, Turkey, China, Netherlands, USA, Japan, Australia, Syria, Venezuela, Mexico, and Nigeria. The age ranges from 8 to over 80 years, with most cases observed among older ages. The majority of cases occurred after cataract surgery. Anterior chamber inflammation and diffuse corneal

edema were the most clinical presentation among patients. Besides, most cases were treated successfully with steroids (Table 2).

CONCLUSIONS

Toxic anterior segment syndrome (TASS) remains a serious postoperative complication that arises primarily after cataract surgery. The most reported reasons for TASS include toxic intraocular agents, inadequate instrumental sterilizations, and contaminated intraocular solutions. Corticosteroids continue to be an effective therapy for the majority of TASS cases. Additional medications, like topical NaCl, timolol, and atropine, may be added based on patients' clinical presentations. Still, some cases required surgical intervention, such as keratoplasty, anterior chamber washout, IOL removal, and vitrectomy. Preventive strategies, such as sterilizing ophthalmic instruments, can decrease the incidence of TASS more and more.

Authorship Contribution: All authors share equal effort contribution towards (1) substantial contributions to conception and design, acquisition, analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the manuscript version to be published. Yes.

Potential Conflicts of Interest: None

Competing Interest: None

Acceptance Date: 01 December 2025

REFERENCE

1. Meltzer D W. Sterile hypopyon following intraocular lens surgery. *Arch Ophthalmol* 1980;98(1):100–4.
2. Monson M C, Mamalis N, Olson R J. Toxic anterior segment inflammation following cataract surgery. *J Cataract Refract Surg* 1992;18(2):184–9.
3. Li H, Tsoulos K T, Guan J J, et al. Toxic Anterior Segment Syndrome. In: Chakrabarti M, Chakrabarti A, eds. *Posterior Segment Complications of Cataract Surgery*. Spr 2020;1(1):95–106.
4. Piest K L, Kincaid M C, Tetz M R, et al. Localized endophthalmitis: a newly described cause of the so-called toxic lens syndrome. *J Cataract Refract Surg* 1987;13(5):498–510.
5. Mamalis N, Edelhauser H F, Dawson D G, et al. Toxic anterior segment syndrome. *J Cataract Refract Surg* 2006;32(2):324–33.
6. Breebaart A C, Nuyts R M, Pels E, et al. Toxic endothelial cell destruction of the cornea after routine extracapsular cataract surgery. *Arch Ophthalmol* 1990;108(8):1121–5.
7. Apple D J, Mamalis N, Loftfield K, et al. Complications of intraocular lenses. A historical and histopathological review. *Surv Ophthalmol* 1984;29(1):1–54.
8. Patel S B, Reddy N K, He Y G. Toxic posterior segment syndrome after dropless cataract surgery with compounded Triamcinolone-Moxifloxacin. *Retina* 2020;40(3):446–55.
9. Park C Y, Lee J K, Chuck R S. Toxic anterior segment syndrome—an updated review. *BMC Ophthalmol* 2018;18(1):276–85.
10. Sevimli N, Karadag R, Cakici O, et al. Toxic anterior segment syndrome following deep anterior lamellar keratoplasty. *Arq Bras Oftalmol* 2016;79(5):330–2.
11. Maier P, Birnbaum F, Böhringer D, et al. Toxic anterior segment syndrome following penetrating keratoplasty. *Arch Ophthalmol* 2008;126(12):1677–81.
12. Suzuki T, Ohashi Y, Oshika T, et al. Outbreak of late-onset toxic anterior segment syndrome after implantation of one-piece intraocular lenses. *Am J Ophthalmol* 2015;159(5):934–9.
13. Miyake G, Ota I, Miyake K, et al. Late-onset toxic anterior segment syndrome. *J Cataract Refract Surg* 2015;41(3):666–9.
14. Gonul S, Ozturk B T. Outbreak of Late-Onset Toxic Anterior Segment Syndrome After Implantation of One-Piece Intraocular Lenses. *Am J Ophthalmol* 2015;160(1):208–9.
15. Hernandez-Bogantes E, Navas A, Naranjo A, et al. Toxic anterior segment syndrome: A review. *Surv Ophthalmol* 2019;64(4):463–76.
16. Green K, Hull D S, Vaughn E D, et al. Rabbit endothelial response to ophthalmic preservatives. *Arch Ophthalmol* 1977;95(12):2218–21.
17. Parikh C, Sippy B D, Martin D F, et al. Effects of enzymatic sterilization detergents on the corneal endothelium. *Arch Ophthalmol* 2002;120(2):165–72.
18. Carter L M, Duncan G, Rennie G K. Effects of detergents on the ionic balance and permeability of isolated bovine cornea. *Exp Eye Res* 1973;17(5):409–16.
19. Kim J H. Intraocular inflammation of denatured viscoelastic substance in cases of cataract extraction and lens implantation. *J Cataract Refract Surg* 1987;13(5):537–42.
20. Parikh C H, Edelhauser H F. Ocular surgical pharmacology: corneal endothelial safety and toxicity. *Curr Opin Ophthalmol* 2003;14(4):178–85.
21. Gonnering R, Edelhauser H F, Van Horn D L, et al. The pH tolerance of rabbit and human corneal endothelium. *Invest Ophthalmol Vis Sci* 1979;18(4):373–90.
22. Edelhauser H F, Van Horn D L, Schultz R O, et al. Comparative toxicity of intraocular irrigating solutions on the corneal endothelium. *Am J Ophthalmol* 1976;81(4):473–81.
23. Kreisler K R, Martin S S, Young C W, et al. Postoperative inflammation following cataract extraction caused by bacterial contamination of the cleaning bath detergent. *J Cataract Refract Surg* 1992;18(1):106–10.
24. Ozcelik N D, Eltutar K, Bilgin B. Toxic anterior segment syndrome after uncomplicated cataract surgery. *Eur J Ophthalmol* 2010;20(1):106–14.
25. Lim C H, Wong N J, Ng C H, et al. Toxic anterior segment syndrome in a tertiary Australian healthcare institution. *Clin Exp Ophthalmol* 2017;45(7):750–52.
26. Kim S Y, Park Y H, Kim H S, et al. Bilateral toxic anterior segment syndrome after cataract surgery. *Can J Ophthalmol* 2007;42(3):490–1.
27. Mamalis N. Anatomy of a TASS outbreak. *J Cataract Refract Surg* 2007;33(3):357–8.
28. Johnston J. Toxic anterior segment syndrome—more than sterility meets the eye. *Aorn J* 2006;84(6):969–84.
29. Eydelman M B, Tarver M E, Calogero D, et al. The Food and Drug Administration's Proactive toxic anterior segment syndrome Program. *Ophthalmology* 2012;119(7):1297–302.
30. Centers for Disease Control and Prevention (CDC). Toxic anterior segment syndrome after cataract surgery—Maine, 2006. *MMWR Morb Mortal Wkly Rep* 2007;56(25):629–30.
31. Shouchane-Blum K, Dotan A, Bahar I. The evolution of toxic anterior segment syndrome. *Curr Opin Ophthalmol* 2019;30(1):50–5.
32. Sengupta S, Chang D F, Gandhi R, et al. Incidence and long-term outcomes of toxic anterior segment syndrome at Aravind Eye Hospital. *J Cataract Refract Surg* 2011;37(9):1673–8.
33. Cutler Peck C M, Brubaker J, Clouser S, et al. Toxic anterior segment syndrome: common causes. *J Cataract Refract Surg* 2010;36(7):1073–80.
34. Yazgan S, Celik U, Ayar O, et al. The role of patient's systemic characteristics and plateletcrit in developing toxic anterior segment syndrome after uneventful phaco surgery: A case-control study. *Int Ophthalmol* 2018;38(1):43–52.
35. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. *Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol* 1995;113(12):1479–96.
36. Bodnar Z, Clouser S, Mamalis N. Toxic anterior segment syndrome: Update on the most common causes. *J Cataract Refract Surg* 2012;38(11):1902–10.
37. Kaplan A, Tas M D, Selver O B. Unusual Inflammatory Clinical Presentation After Cataract Surgery and that Thought-provoking Question: Is this Infection or Toxic Anterior Segment Syndrome? *Middle East Afr J Ophthalmol* 2022;29(4):196–9.
38. Sengillo J D, Chen Y, Perez Garcia D, et al. Postoperative Endophthalmitis and Toxic Anterior Segment Syndrome Prophylaxis: 2020 Update. *Ann Transl Med* 2020;8(22):1548–56.
39. Pathengay A, Khera M, Das T, et al. Acute Postoperative Endophthalmitis Following Cataract Surgery: A Review. *Asia Pac J Ophthalmol (Phila)* 2012;1(1):35–42.
40. Wickremasinghe S S, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreal injections of bevacizumab for treatment of neovascular age-related macular degeneration. *Ophthalmology* 2008;115(11):1911–5.
41. Wang F, Yu S, Liu K, et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. *Ophthalmology* 2013;120(2):355–61.
42. Verma L, Malik A, Maharana P K, et al. Toxic anterior segment syndrome (TASS): A review and update. *Indian J Ophthalmol* 2024;72(1):11–8.

43. Fielden M, Nelson B, Kherani A. Acute intraocular inflammation following intravitreal injection of bevacizumab--a large cluster of cases. *Acta Ophthalmol* 2011;89(8):664–5.
44. Menke A M. Endophthalmitis and TASS: Prevention, Diagnosis, Investigation, Response [internet]. 2025 [accessed on March 13, 2025].
45. Ganesan N, Srinivasan R, Kaliaperumal S. Toxic anterior segment syndrome and Urrets-Zavalía syndrome: Spectrum of the same entity? *Oman J Ophthalmol* 2023;16(1):39–44.
46. Kutluksaman B, Kara S G. Toxic Anterior Segment Syndrome (tass) : Review. *Id Health Science* 2024;2(3):99–104.
47. Moyle W, Yee R D, Burns J K, et al. Two consecutive clusters of toxic anterior segment syndrome. *Optom Vis Sci* 2013;90(1):11–23.
48. Sorkin N, Varssano D. Toxic Anterior Segment Syndrome following a Triple Descemet's Stripping Automated Endothelial Keratoplasty Procedure. *Case Rep Ophthalmol* 2012;3(3):406–9.
49. Choi J S, Shyn K H. Development of toxic anterior segment syndrome immediately after uneventful phaco surgery. *Korean J Ophthalmol* 2008;22(4):220–7.
50. Koban Y, Genc S, Bilgin G, et al. Toxic Anterior Segment Syndrome following Phacoemulsification Secondary to Overdose of Intracameral Gentamicin. *Case Rep Med* 2014;2014(1):1-11.
51. Ginger-Eke H, Ogbonnaya C, Odayappan A, et al. Toxic anterior segment syndrome following trabeculectomy with mitomycin C. *GMS Ophthalmol Cases* 2023;13(17):1-13.
52. Ruiz-Lozano R E, Ramos-Davila E M, Garza-Garza L A, et al. Challenges in the diagnosis and management of simultaneous, bilateral, toxic anterior segment syndrome after phacorefractive surgery. *Digit J Ophthalmol* 2023;29(2):40–4.
53. Durand M L. Endophthalmitis. *Clin Microbiol Infect* 2013;19(3):227–34.
54. Eissa S A, Sadek S H, El-Deeb M W. Anterior Chamber Angle Evaluation following Phakic Posterior Chamber Collamer Lens with CentraFLOW and Its Correlation with ICL Vault and Intraocular Pressure. *J Ophthalmol* 2016;2016(1):1-13.
55. Fibrin. Reactions. *Weekly* 2020;1785(1):232–32.
56. Unal M, Yücel I, Akar Y, et al. Outbreak of toxic anterior segment syndrome associated with glutaraldehyde after cataract surgery. *J Cataract Refract Surg* 2006;32(10):1696–701.
57. Pineda R, 2nd, Jain V, Gupta P, et al. Descemet's stripping endothelial keratoplasty: an effective treatment for toxic anterior segment syndrome with histopathologic findings. *Cornea* 2010;29(6):694–7.
58. Kumaran N, Larkin G, Hollick E J. Sterile postoperative endophthalmitis following HOYA IOL insertion. *Eye (Lond)* 2014;28(11):1382-9.
59. Chang D F, Mamalis N. Guidelines for the cleaning and sterilization of intraocular surgical instruments. *J Cataract Refract Surg* 2018;44(6):765–73.
60. Jun E J, Chung S K. Toxic anterior segment syndrome after cataract surgery. *J Cataract Refract Surg* 2010;36(2):344–6.
61. Huang Y, Dai Y, Wu X, et al. Toxic anterior segment syndrome after pediatric cataract surgery. *J aapos* 2010;14(5):444–6.
62. van Philips L A. Toxic anterior segment syndrome after foldable artiflex iris-fixated phakic intraocular lens implantation. *J Ophthalmol* 2011;2011(9):1-18.
63. Lee M H, Cugley D, Atik A, et al. Endophthalmitis or toxic anterior segment syndrome? *Clin Exp Optom* 2017;100(1):94–5.
64. Ahmad A A, Hamwi A O, Hasan R B, et al. A case report of toxic anterior segment syndrome, A rare complication after laser in situ keratomileusis. *ReseaSq* 2021;1(1):1-8.
65. Arıcı C, Mergen B, Kılıçarslan O, et al. Diffuse Corneal Edema after Uneventful Pterygium Surgery: Toxic Anterior Segment Syndrome or Toxic Keratopathy? *Turk J Ophthalmol* 2022;52(1):69–71.
66. Gil-Martínez T M, Herrera M J, Vera V. Two Cases of Consecutive Toxic Anterior Segment Syndrome after Uneventful Trabeculectomy Surgeries in a Tertiary Center. *Case Rep Ophthalmol* 2022;13(1):234–42.